Monovalent Degrader Modalities to Deliver High Impact Therapies

Posters & Presentations

Plexium has a highly differentiated drug discovery approach, which has led to the discovery of novel, selective, targeted protein degraders with the potential to address diseases with significant unmet medical needs.

Posters & Presentations

Advantages of Monovalent Targeted Protein Degraders

  • Monovalent degraders are drug-like, orally available small molecules
  • Avoids PK challenges and potential for hook effect historically associated with PROTACS
  • Event-driven degrader pharmacology amplifies selectivity over inhibitors, avoiding off-target toxicities
Plexium Comparison

Two Modalities Offer Therapeutic Optionality

Monovalent Direct Degraders

  • Small drug-like molecules that bind to the protein of interest (POU)
  • Rapidly design Direct Degraders using existing chemical starting points
  • Plexium’s cell-based screening platform has Identited multiple novel E3 ligases and expanded the TPD toolbox
  • Chemistry design principles transferable across targets

Molecular Glue Degraders

  • Small drug-like molecules that bind E3 ligases to induce POl degradation
  • Plexium has implemented a Molecular Glue strategy to target
    “undruggable” proteins
  • Large on-bead library for screening and accelerating hit identification
  • “Focused diversity” around key E3 binding elements
Plexium Degrader Glue

Interested in Partnering?

Together, we can accelerate the development of transformative medicines.

Contact Us